MedTrace Logo

Observational Registry Evaluating the Clinical Impact of the Blood-Based Biomarker Test for Early-Stage Pancreatic Ductal Adenocarcinoma

NCT07805681 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2026-09-04

No results posted yet for this study

Summary

The goal of this observational registry is to examine the changes made to pancreatic cancer surveillance management following the real-world clinical use of PancreaSure testing among individuals at increased risk for pancreatic ductal adenocarcinoma. The main question it aims to answer is, does surveillance management and intent change following the return of PancreaSure binary results.

Conditions

  • PDAC - Pancreatic Ductal Adenocarcinoma
  • Pancreatic Cancer Stage I
  • Pancreatic Cancer Stage II
  • Cancer Diagnosis

Sponsors & Collaborators

  • Immunovia, Inc.

    lead INDUSTRY

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2028-01-31
Completion
2029-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07805681 on ClinicalTrials.gov